论文部分内容阅读
目的研究硼替佐米治疗多发性骨髓瘤肾病早期肾损害的临床疗效。方法选取多发性骨髓瘤肾病早期肾损害患者200例,随机分为观察组和对照组各100例,对照组给予环磷酰胺+地塞米松+沙利度胺治疗,观察组给予硼替佐米+地塞米松+沙利度胺治疗,比较2组患者治疗前后胱抑素C(Cys-C)、血视黄醇结合蛋白(RBP)、血β2微球蛋白(β2-MG)、24h尿蛋白定量与不良反应发生情况。结果治疗后2组患者Cys-C、RBP、β2-MG及24h尿蛋白定量均较治疗前明显改善,且观察组改善情况优于对照组,差异均有统计学意义(P<0.05)。观察组不良反应发生率为10.00%,低于对照组的32.00%,差异有统计学意义(P<0.05)。结论硼替佐米治疗多发性骨髓瘤肾病早期肾损害,效果确切,安全性高,值得临床推广。
Objective To study the clinical efficacy of bortezomib in the treatment of early stage renal nephropathy with multiple myeloma. Methods 200 cases of multiple myeloma nephropathy in patients with early renal damage were randomly divided into observation group and control group of 100 cases, the control group was given cyclophosphamide + dexamethasone + thalidomide treatment, the observation group was given bortezomib + Dexamethasone + thalidomide treatment. The levels of cystatin C (Cys-C), RBP, β2-MG, 24h urinary protein Quantitative and adverse reactions occurred. Results The Cys-C, RBP, β2-MG and 24-hour urinary protein in two groups after treatment were significantly improved compared with that before treatment, and the improvement in the observation group was better than that in the control group (P <0.05). The incidence of adverse reactions in the observation group was 10.00%, which was lower than that in the control group (32.00%), the difference was statistically significant (P <0.05). Conclusion Bortezomib treatment of multiple myeloma nephropathy early renal damage, the exact effect, high safety, worthy of clinical promotion.